vs
Side-by-side financial comparison of Enphase Energy (ENPH) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Enphase Energy is the larger business by last-quarter revenue ($282.9M vs $177.4M, roughly 1.6× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -2.6%, a 4.3% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -20.6%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -3.4%).
Enphase Energy, Inc. is an American energy technology company headquartered in Fremont, California, that develops and manufactures solar micro-inverters, battery energy storage, and EV charging stations primarily for residential customers. Enphase was established in 2006 and is the first company to successfully commercialize solar micro-inverters, which convert the direct current (DC) power generated by solar panels into grid-compatible alternating current (AC) for use or export.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ENPH vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $282.9M | $177.4M |
| Net Profit | $-7.4M | $2.9M |
| Gross Margin | 35.5% | — |
| Operating Margin | 54.0% | 3.9% |
| Net Margin | -2.6% | 1.6% |
| Revenue YoY | -20.6% | 5.0% |
| Net Profit YoY | -124.9% | — |
| EPS (diluted) | $-0.06 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $282.9M | $177.4M | ||
| Q4 25 | $343.3M | $196.9M | ||
| Q3 25 | $410.4M | $179.5M | ||
| Q2 25 | $363.2M | $181.1M | ||
| Q1 25 | $356.1M | $168.9M | ||
| Q4 24 | $382.7M | $187.3M | ||
| Q3 24 | $380.9M | $168.6M | ||
| Q2 24 | $303.5M | $178.0M |
| Q1 26 | $-7.4M | $2.9M | ||
| Q4 25 | $38.7M | — | ||
| Q3 25 | $66.6M | $5.4M | ||
| Q2 25 | $37.1M | $-4.8M | ||
| Q1 25 | $29.7M | $4.8M | ||
| Q4 24 | $62.2M | — | ||
| Q3 24 | $45.8M | $-143.5M | ||
| Q2 24 | $10.8M | $18.9M |
| Q1 26 | 35.5% | — | ||
| Q4 25 | 44.3% | 79.5% | ||
| Q3 25 | 47.8% | 80.9% | ||
| Q2 25 | 46.9% | 77.4% | ||
| Q1 25 | 47.2% | 79.7% | ||
| Q4 24 | 51.8% | 78.7% | ||
| Q3 24 | 46.8% | 76.9% | ||
| Q2 24 | 45.2% | 75.1% |
| Q1 26 | 54.0% | 3.9% | ||
| Q4 25 | 6.5% | 1.2% | ||
| Q3 25 | 16.1% | 3.5% | ||
| Q2 25 | 10.2% | 4.7% | ||
| Q1 25 | 9.0% | 1.2% | ||
| Q4 24 | 14.3% | 13.2% | ||
| Q3 24 | 13.1% | -82.8% | ||
| Q2 24 | 0.6% | 15.9% |
| Q1 26 | -2.6% | 1.6% | ||
| Q4 25 | 11.3% | — | ||
| Q3 25 | 16.2% | 3.0% | ||
| Q2 25 | 10.2% | -2.7% | ||
| Q1 25 | 8.3% | 2.8% | ||
| Q4 24 | 16.2% | — | ||
| Q3 24 | 12.0% | -85.1% | ||
| Q2 24 | 3.6% | 10.6% |
| Q1 26 | $-0.06 | $0.07 | ||
| Q4 25 | $0.29 | $0.05 | ||
| Q3 25 | $0.50 | $0.12 | ||
| Q2 25 | $0.28 | $-0.11 | ||
| Q1 25 | $0.22 | $0.10 | ||
| Q4 24 | $0.46 | $0.38 | ||
| Q3 24 | $0.33 | $-3.11 | ||
| Q2 24 | $0.08 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.5M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $653.9M |
| Total Assets | $2.7B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $497.5M | $144.3M | ||
| Q4 25 | $1.5B | $238.4M | ||
| Q3 25 | $1.5B | $246.3M | ||
| Q2 25 | $1.5B | $445.9M | ||
| Q1 25 | $1.5B | $493.6M | ||
| Q4 24 | $1.6B | $484.6M | ||
| Q3 24 | $1.8B | $453.8M | ||
| Q2 24 | $1.6B | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $372.2M | ||
| Q3 25 | $1.2B | $376.7M | ||
| Q2 25 | $1.2B | $580.5M | ||
| Q1 25 | $1.2B | $583.4M | ||
| Q4 24 | $1.3B | $585.3M | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — |
| Q1 26 | $1.1B | $653.9M | ||
| Q4 25 | $1.1B | $693.1M | ||
| Q3 25 | $995.0M | $727.2M | ||
| Q2 25 | $880.6M | $757.8M | ||
| Q1 25 | $810.7M | $798.5M | ||
| Q4 24 | $833.0M | $778.3M | ||
| Q3 24 | $931.4M | $749.6M | ||
| Q2 24 | $884.5M | $879.3M |
| Q1 26 | $2.7B | $1.2B | ||
| Q4 25 | $3.5B | $1.3B | ||
| Q3 25 | $3.3B | $1.3B | ||
| Q2 25 | $3.2B | $1.5B | ||
| Q1 25 | $3.1B | $1.6B | ||
| Q4 24 | $3.2B | $1.6B | ||
| Q3 24 | $3.3B | $1.5B | ||
| Q2 24 | $3.2B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 1.11× | 0.54× | ||
| Q3 25 | 1.21× | 0.52× | ||
| Q2 25 | 1.37× | 0.77× | ||
| Q1 25 | 1.48× | 0.73× | ||
| Q4 24 | 1.56× | 0.75× | ||
| Q3 24 | 1.40× | — | ||
| Q2 24 | 1.47× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $102.9M | — |
| Free Cash FlowOCF − Capex | $83.0M | — |
| FCF MarginFCF / Revenue | 29.3% | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $145.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $102.9M | — | ||
| Q4 25 | $47.6M | $43.7M | ||
| Q3 25 | $13.9M | $60.8M | ||
| Q2 25 | $26.6M | $12.0M | ||
| Q1 25 | $48.4M | $35.5M | ||
| Q4 24 | $167.3M | $33.1M | ||
| Q3 24 | $170.1M | $53.9M | ||
| Q2 24 | $127.1M | $53.2M |
| Q1 26 | $83.0M | — | ||
| Q4 25 | $37.8M | $43.5M | ||
| Q3 25 | $5.9M | $57.0M | ||
| Q2 25 | $18.4M | $9.3M | ||
| Q1 25 | $33.8M | $26.9M | ||
| Q4 24 | $159.2M | $31.0M | ||
| Q3 24 | $161.6M | $49.8M | ||
| Q2 24 | $117.4M | $51.6M |
| Q1 26 | 29.3% | — | ||
| Q4 25 | 11.0% | 22.1% | ||
| Q3 25 | 1.4% | 31.7% | ||
| Q2 25 | 5.1% | 5.1% | ||
| Q1 25 | 9.5% | 15.9% | ||
| Q4 24 | 41.6% | 16.6% | ||
| Q3 24 | 42.4% | 29.6% | ||
| Q2 24 | 38.7% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | 0.1% | ||
| Q3 25 | 2.0% | 2.2% | ||
| Q2 25 | 2.3% | 1.5% | ||
| Q1 25 | 4.1% | 5.1% | ||
| Q4 24 | 2.1% | 1.1% | ||
| Q3 24 | 2.2% | 2.4% | ||
| Q2 24 | 3.2% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.23× | — | ||
| Q3 25 | 0.21× | 11.20× | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 1.63× | 7.37× | ||
| Q4 24 | 2.69× | — | ||
| Q3 24 | 3.72× | — | ||
| Q2 24 | 11.73× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ENPH
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
